Key result
Myocardial gadolinium partition coefficient is higher in chronic MI scar than acute myocarditis, reaching ~0.77.
Why the study?
Although the myocardial gadolinium partition coefficient differs numerically between chronic ischemic scar and acute myocarditic injury, fundamental domains including its temporal evolution, microstructural determinants, multi-compartment kinetics, and prognostic implications remain poorly characterized.
Does the myocardial gadolinium partition coefficient (λ) derived from quantitative CMR T1 mapping discriminate between evolving inflammatory myocardial injury and chronic ischemic scar?
Does the myocardial gadolinium partition coefficient (λ) derived from quantitative CMR T1 mapping discriminate between evolving inflammatory myocardial injury and chronic ischemic scar?
This review highlights the potential of the CMR-derived myocardial gadolinium partition coefficient (λ) to differentiate denser chronic ischemic scar from acute inflammatory injury, while outlining major evidence gaps required to validate it as a clinical biomarker.
Answers are grounded in this paper and cite their sources.
λ may differentiate chronic MI scar from acute myocarditis on CMR; leaves open longitudinal and histological validation before clinical use.
The myocardial tissue-blood partition coefficient (PC or λ) of gadolinium-based contrast agents is derived from pre- and post-contrast T1 mapping (typically via MOLLI or similar sequences) as: [ λ ≈ {Δ R1myocardium}{Δ R1blood} ] where ( R1 = 1/T1 ). When corrected for hematocrit, it yields the extracellular volume fraction (ECV), a quantitative marker of the myocardial extracellular space. Elevated λ/ECV reflects expansion due to edema, inflammation, necrosis, or replacement fibrosis. The 2019 pilot study (Canadian Journal of Cardiology) measured λ after 0.1 mmol/kg Gd-BOPTA at 3 T in healthy volunteers, chronic MI patients, and acute myocarditis patients. Key findings included: Whole-LV λ was modestly higher in chronic MI with focal LGE than in MI without scar, but not markedly different from volunteers or myocarditis overall. Focal scar λ was significantly higher in chronic MI (≈0.77) than in acute myocarditis (≈0.60). λ correlated with scar burden (% LGE) in both disease groups. The authors concluded that λ may index disease activity and scar density, with denser scarring in chronic ischemic injury than acute inflammatory injury. This sits within a broader literature (dating to early 2000s work by Flacke, Thornhill, Prato and others) showing that λ is elevated in both acute and chronic infarction relative to remote/normal myocardium, that equilibrium assumptions hold reasonably well after bolus or infusion, and that different gadolinium chelates (Gd-DTPA vs protein-binding agents such as Gd-BOPTA) produce different absolute λ values and equilibration kinetics. Three-compartment pharmacokinetic models have been applied mainly to chronic MI, revealing increased fibrotic trapping volumes. Parallel work has linked elevated λ/ECV to diffuse fibrosis in dilated cardiomyopathy, amyloid, and other non-ischemic diseases, and to functional parameters such as strain and ejection fraction. Expansion and knowledge gaps While the pilot established feasibility and a numerical difference between chronic ischemic scar and acute myocarditic injury, several fundamental domains remain poorly characterized or essentially unexplored: Temporal evolution of λ within the same patient from acute myocarditis through healing or progression to chronic inflammatory cardiomyopathy (virtually no longitudinal serial-mapping data exist). Molecular and microstructural determinants of the observed density difference (collagen subtype, cross-linking, residual edema, inflammatory cell infiltrate, microvascular integrity) — histological validation of λ differences between the two injury types is sparse. Multi-compartment kinetic modeling of gadolinium in inflammatory versus ischemic injury; most sophisticated modeling remains confined to chronic MI. Influence of contrast-agent physicochemical properties (relaxivity, protein binding, molecular size), field strength, acquisition timing, and post-processing methods on the ability of λ to discriminate reversible edema/inflammation from irreversible fibrosis. Prognostic and therapeutic implications: whether serial λ changes predict recovery of function, arrhythmic risk, or response to anti-inflammatory or antifibrotic therapy is unknown. Behavior of λ in mixed or overlapping phenotypes (myocarditis mimicking infarction, infarction with secondary inflammation, chronic myocarditis evolving into dilated cardiomyopathy) and in other infiltrative or storage diseases. Standardization and reproducibility across centers, scanners, and analysis platforms; the literature remains dominated by small single-center pilot or proof-of-concept studies. These gaps leave open the possibility that λ could evolve from a descriptive tissue-characterization metric into a pathophysiological biomarker capable of distinguishing injury mechanisms, staging disease activity, and guiding therapy — domains for which current evidence is essentially absent.
No takes yet. Share an insight, caveat, or question.
Bravo et al. (2026) conducted a review in Chronic myocardial infarction and acute myocarditis. Myocardial gadolinium partition coefficient (λ) via T1 mapping vs. Chronic myocardial infarction vs acute myocarditis vs healthy volunteers was evaluated on Focal scar myocardial gadolinium partition coefficient (λ). Myocardial gadolinium partition coefficient (λ) is higher in chronic MI focal scar than in acute myocarditis, though major longitudinal and histological validation gaps remain.
Synapse has enriched 10 related papers. Consider them for comparative context: